Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2004 5
2005 2
2006 3
2007 5
2008 3
2009 2
2011 1
2012 1
2013 2
2014 2
2015 2
2016 4
2017 4
2018 4
2019 1
2020 2
2022 8
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Nomogram Predicting Locally Advanced Prostate Cancer in Patients with Clinically Organ-Confined Disease Who Underwent Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).
Kawase M, Goto T, Ebara S, Tatenuma T, Sasaki T, Ishihara T, Ikehata Y, Nakayama A, Toide M, Yoneda T, Sakaguchi K, Teishima J, Kobayashi T, Makiyama K, Inoue T, Kitamura H, Saito K, Koga F, Urakami S, Koie T. Kawase M, et al. Among authors: ebara s. Ann Surg Oncol. 2023 Oct;30(11):6925-6933. doi: 10.1245/s10434-023-13747-2. Epub 2023 Jun 20. Ann Surg Oncol. 2023. PMID: 37338747
A case of mucosal-associated lymphoid tissue lymphoma of the urachus.
Tsuboi K, Bekku K, Haisa K, Kajihara Y, Tsugawa T, Inoue Y, Sako T, Murao W, Ebara S. Tsuboi K, et al. Among authors: ebara s. IJU Case Rep. 2023 Jun 14;6(4):253-256. doi: 10.1002/iju5.12599. eCollection 2023 Jul. IJU Case Rep. 2023. PMID: 37405026 Free PMC article.
Comparison of perioperative outcomes and complications between intracorporeal, extracorporeal, and hybrid ileal conduit urinary diversion during robot-assisted radical cystectomy: a comparative propensity score-matched analysis from nationwide multi-institutional study in Japan.
Morizane S, Nakane K, Tanaka T, Zennami K, Muraoka K, Ebara S, Miura N, Uemura K, Sobu R, Hoshi A, Taoka R, Sugimoto M, Noma H, Sunada H, Nishiyama H, Habuchi T, Ikeda I, Saika T, Makiyama K, Shiroki R, Masumori N, Koie T, Takenaka A. Morizane S, et al. Among authors: ebara s. Int J Clin Oncol. 2024 Jan;29(1):64-71. doi: 10.1007/s10147-023-02425-8. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37864612
Prognostic differences among Grade Group 4 subgroups in robotic-assisted radical prostatectomy.
Sasaki T, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kato D, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Inoue T. Sasaki T, et al. Among authors: ebara s. BJUI Compass. 2022 Jun 2;3(5):392-399. doi: 10.1002/bco2.160. eCollection 2022 Sep. BJUI Compass. 2022. PMID: 35950038 Free PMC article.
Clinical Factors Associated With Pathological Grade Group 1 Patients in D'Amico Intermediate-Risk Group Following Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).
Sugino Y, Sasaki T, Ebara S, Tatenuma T, Ikehata Y, Nakayama A, Kawase M, Toide M, Yoneda T, Sakaguchi K, Teishima J, Makiyama K, Kitamura H, Saito K, Koie T, Koga F, Urakami S, Inoue T. Sugino Y, et al. Among authors: ebara s. Clin Genitourin Cancer. 2022 Dec;20(6):593-600. doi: 10.1016/j.clgc.2022.06.005. Epub 2022 Jun 9. Clin Genitourin Cancer. 2022. PMID: 35773146
61 results